|
|
News Breaks | | | | February 18, 2013 | | 17:41 EDT |  | CHE | Chemed sees FY13 EPS of $5.65-$5.80, consensus $5.47
| |
|
News For CHE From The Last 14 Days Check below for free stories on CHE the last two weeks. |
|
|
| May 16, 2013 | | 15:41 EDT |  | CHE | Chemed says government to intervene in previously disclosed qui tam complaints
Chemed disclosed in a regulatory filing that on May 6, the U.S. District Court for the Western District of Missouri, at the request of the government, unsealed a qui tam complaint against VITAS and VITAS Healthcare Corporation of California. The complaint alleges that VITAS’ Los Angeles program falsely certified and recertified patients as eligible for the Medicare Hospice Benefit. It alleges violations of the false claims act and seeks treble damages, civil penalties, recovery of costs, attorneys’ fees and expenses, and pre- and post-judgment interest. On May 9 and 10, respectively, the government moved to intervene partially in the previously disclosed qui tam complaints filed in U.S. District Courts for the Western District of Texas and Northern District of Illinois, respectively, and transfer the cases to the U.S. District Court for the Western District of Missouri and consolidate such cases. In its motions, the government stated that it seeks to intervene partially on the allegations that VITAS submitted or caused the submission of false or fraudulent claims for continuous home care and routine home care on behalf of certain ineligible Medicare beneficiaries. | | | May 10, 2013 | | 13:01 EDT | | CHE | Citron Research says Chemed shares headed for teens
 Subscribe for More Information | | | 12:54 EDT | | CHE | Chemed mentioned cautiously by Citron Research
Subscribe for More Information | |
|
|
|
|
|
|
